Evaluation of serum miRNAs expression in frail and robust subjects undergoing multicomponent exercise protocol (VIVIFRAIL)
Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene...
Saved in:
| Published in | Journal of translational medicine Vol. 21; no. 1; pp. 67 - 9 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
02.02.2023
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene expression; miRNAs are present in serum and are considered potential biomarkers for several diseases. Serum concentration of miR-451a, miR-93-5p, miR-155-5p, miR-421-3p, miR-425-5p, miR-495-3p and miR-744-5p was recently shown to be altered in sarcopenic patients.
We verified if a particular miRNAs pattern could be detected in frailty as well by analyzing these molecules in 50 frail and 136 robust subjects. Additionally, a subgroup of these subjects (15 frail and 30 robust) underwent a 12-week program based on a multicomponent exercise protocol (VIVIFRAIL) consisting of resistance training, gait retraining, and balance training. After the program, serum miRNAs concentration was measured again, to verify whether the physical activity had an effect on their concentration. Moreover, clinical characteristics and indicators of physical performance of all subjects were compared before and after intervention to verify the effect of the VIVIFRAIL program.
At the end of the multicomponent exercise program, Short Physical Performance Battery (SPPB) score as well right and left handgrip (p < 0.05) were significantly increased in frail subjects; right and left handgrip significantly were increased also in robust subjects (p < 0.05). Interestingly, the variation of SPPB was significantly higher in frail compared to robust subjects (p < 0.0001). Moreover, at the end of the program, in frail compared to robust subjects: miR-451a serum concentration was significantly increased (frail: 6.59 × 10
; 1.12 × 10
-2.5 × 10
c/ng; robust: 2.31 × 10
; 1.94 × 10
-2.01 × 10
c/ng) (p < 0.05); and 2) miR-93-5p and miR-495-3p serum concentration was reduced, whereas that of miR-155-5p was significantly increased (p < 0.05 in both cases). Serum concentration of miR-93-5p and miR-495-3p was decreased, and that of miR-155-5p was increased at the end of the program in robust subjects alone, statistical significance being reached for miR-93-5p alone (p = 0.02).
These results suggest that serum miR-451a should be investigated as a potential biomarker for frailty and show that the VIVIFRAIL multicomponent program modulates circulatory miRNAs expression, at least in older adults. |
|---|---|
| AbstractList | BackgroundFrailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene expression; miRNAs are present in serum and are considered potential biomarkers for several diseases. Serum concentration of miR-451a, miR-93-5p, miR-155-5p, miR-421-3p, miR-425-5p, miR-495-3p and miR-744-5p was recently shown to be altered in sarcopenic patients.MethodsWe verified if a particular miRNAs pattern could be detected in frailty as well by analyzing these molecules in 50 frail and 136 robust subjects. Additionally, a subgroup of these subjects (15 frail and 30 robust) underwent a 12-week program based on a multicomponent exercise protocol (VIVIFRAIL) consisting of resistance training, gait retraining, and balance training. After the program, serum miRNAs concentration was measured again, to verify whether the physical activity had an effect on their concentration. Moreover, clinical characteristics and indicators of physical performance of all subjects were compared before and after intervention to verify the effect of the VIVIFRAIL program.ResultsAt the end of the multicomponent exercise program, Short Physical Performance Battery (SPPB) score as well right and left handgrip (p < 0.05) were significantly increased in frail subjects; right and left handgrip significantly were increased also in robust subjects (p < 0.05). Interestingly, the variation of SPPB was significantly higher in frail compared to robust subjects (p < 0.0001). Moreover, at the end of the program, in frail compared to robust subjects: miR-451a serum concentration was significantly increased (frail: 6.59 × 104; 1.12 × 104–2.5 × 105 c/ng; robust: 2.31 × 104; 1.94 × 103–2.01 × 105 c/ng) (p < 0.05); and 2) miR-93-5p and miR-495-3p serum concentration was reduced, whereas that of miR-155-5p was significantly increased (p < 0.05 in both cases). Serum concentration of miR-93-5p and miR-495-3p was decreased, and that of miR-155-5p was increased at the end of the program in robust subjects alone, statistical significance being reached for miR-93-5p alone (p = 0.02).ConclusionThese results suggest that serum miR-451a should be investigated as a potential biomarker for frailty and show that the VIVIFRAIL multicomponent program modulates circulatory miRNAs expression, at least in older adults. Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene expression; miRNAs are present in serum and are considered potential biomarkers for several diseases. Serum concentration of miR-451a, miR-93-5p, miR-155-5p, miR-421-3p, miR-425-5p, miR-495-3p and miR-744-5p was recently shown to be altered in sarcopenic patients. We verified if a particular miRNAs pattern could be detected in frailty as well by analyzing these molecules in 50 frail and 136 robust subjects. Additionally, a subgroup of these subjects (15 frail and 30 robust) underwent a 12-week program based on a multicomponent exercise protocol (VIVIFRAIL) consisting of resistance training, gait retraining, and balance training. After the program, serum miRNAs concentration was measured again, to verify whether the physical activity had an effect on their concentration. Moreover, clinical characteristics and indicators of physical performance of all subjects were compared before and after intervention to verify the effect of the VIVIFRAIL program. At the end of the multicomponent exercise program, Short Physical Performance Battery (SPPB) score as well right and left handgrip (p < 0.05) were significantly increased in frail subjects; right and left handgrip significantly were increased also in robust subjects (p < 0.05). Interestingly, the variation of SPPB was significantly higher in frail compared to robust subjects (p < 0.0001). Moreover, at the end of the program, in frail compared to robust subjects: miR-451a serum concentration was significantly increased (frail: 6.59 × 10 ; 1.12 × 10 -2.5 × 10 c/ng; robust: 2.31 × 10 ; 1.94 × 10 -2.01 × 10 c/ng) (p < 0.05); and 2) miR-93-5p and miR-495-3p serum concentration was reduced, whereas that of miR-155-5p was significantly increased (p < 0.05 in both cases). Serum concentration of miR-93-5p and miR-495-3p was decreased, and that of miR-155-5p was increased at the end of the program in robust subjects alone, statistical significance being reached for miR-93-5p alone (p = 0.02). These results suggest that serum miR-451a should be investigated as a potential biomarker for frailty and show that the VIVIFRAIL multicomponent program modulates circulatory miRNAs expression, at least in older adults. Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene expression; miRNAs are present in serum and are considered potential biomarkers for several diseases. Serum concentration of miR-451a, miR-93-5p, miR-155-5p, miR-421-3p, miR-425-5p, miR-495-3p and miR-744-5p was recently shown to be altered in sarcopenic patients.BACKGROUNDFrailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene expression; miRNAs are present in serum and are considered potential biomarkers for several diseases. Serum concentration of miR-451a, miR-93-5p, miR-155-5p, miR-421-3p, miR-425-5p, miR-495-3p and miR-744-5p was recently shown to be altered in sarcopenic patients.We verified if a particular miRNAs pattern could be detected in frailty as well by analyzing these molecules in 50 frail and 136 robust subjects. Additionally, a subgroup of these subjects (15 frail and 30 robust) underwent a 12-week program based on a multicomponent exercise protocol (VIVIFRAIL) consisting of resistance training, gait retraining, and balance training. After the program, serum miRNAs concentration was measured again, to verify whether the physical activity had an effect on their concentration. Moreover, clinical characteristics and indicators of physical performance of all subjects were compared before and after intervention to verify the effect of the VIVIFRAIL program.METHODSWe verified if a particular miRNAs pattern could be detected in frailty as well by analyzing these molecules in 50 frail and 136 robust subjects. Additionally, a subgroup of these subjects (15 frail and 30 robust) underwent a 12-week program based on a multicomponent exercise protocol (VIVIFRAIL) consisting of resistance training, gait retraining, and balance training. After the program, serum miRNAs concentration was measured again, to verify whether the physical activity had an effect on their concentration. Moreover, clinical characteristics and indicators of physical performance of all subjects were compared before and after intervention to verify the effect of the VIVIFRAIL program.At the end of the multicomponent exercise program, Short Physical Performance Battery (SPPB) score as well right and left handgrip (p < 0.05) were significantly increased in frail subjects; right and left handgrip significantly were increased also in robust subjects (p < 0.05). Interestingly, the variation of SPPB was significantly higher in frail compared to robust subjects (p < 0.0001). Moreover, at the end of the program, in frail compared to robust subjects: miR-451a serum concentration was significantly increased (frail: 6.59 × 104; 1.12 × 104-2.5 × 105 c/ng; robust: 2.31 × 104; 1.94 × 103-2.01 × 105 c/ng) (p < 0.05); and 2) miR-93-5p and miR-495-3p serum concentration was reduced, whereas that of miR-155-5p was significantly increased (p < 0.05 in both cases). Serum concentration of miR-93-5p and miR-495-3p was decreased, and that of miR-155-5p was increased at the end of the program in robust subjects alone, statistical significance being reached for miR-93-5p alone (p = 0.02).RESULTSAt the end of the multicomponent exercise program, Short Physical Performance Battery (SPPB) score as well right and left handgrip (p < 0.05) were significantly increased in frail subjects; right and left handgrip significantly were increased also in robust subjects (p < 0.05). Interestingly, the variation of SPPB was significantly higher in frail compared to robust subjects (p < 0.0001). Moreover, at the end of the program, in frail compared to robust subjects: miR-451a serum concentration was significantly increased (frail: 6.59 × 104; 1.12 × 104-2.5 × 105 c/ng; robust: 2.31 × 104; 1.94 × 103-2.01 × 105 c/ng) (p < 0.05); and 2) miR-93-5p and miR-495-3p serum concentration was reduced, whereas that of miR-155-5p was significantly increased (p < 0.05 in both cases). Serum concentration of miR-93-5p and miR-495-3p was decreased, and that of miR-155-5p was increased at the end of the program in robust subjects alone, statistical significance being reached for miR-93-5p alone (p = 0.02).These results suggest that serum miR-451a should be investigated as a potential biomarker for frailty and show that the VIVIFRAIL multicomponent program modulates circulatory miRNAs expression, at least in older adults.CONCLUSIONThese results suggest that serum miR-451a should be investigated as a potential biomarker for frailty and show that the VIVIFRAIL multicomponent program modulates circulatory miRNAs expression, at least in older adults. Background Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene expression; miRNAs are present in serum and are considered potential biomarkers for several diseases. Serum concentration of miR-451a, miR-93-5p, miR-155-5p, miR-421-3p, miR-425-5p, miR-495-3p and miR-744-5p was recently shown to be altered in sarcopenic patients. Methods We verified if a particular miRNAs pattern could be detected in frailty as well by analyzing these molecules in 50 frail and 136 robust subjects. Additionally, a subgroup of these subjects (15 frail and 30 robust) underwent a 12-week program based on a multicomponent exercise protocol (VIVIFRAIL) consisting of resistance training, gait retraining, and balance training. After the program, serum miRNAs concentration was measured again, to verify whether the physical activity had an effect on their concentration. Moreover, clinical characteristics and indicators of physical performance of all subjects were compared before and after intervention to verify the effect of the VIVIFRAIL program. Results At the end of the multicomponent exercise program, Short Physical Performance Battery (SPPB) score as well right and left handgrip (p < 0.05) were significantly increased in frail subjects; right and left handgrip significantly were increased also in robust subjects (p < 0.05). Interestingly, the variation of SPPB was significantly higher in frail compared to robust subjects (p < 0.0001). Moreover, at the end of the program, in frail compared to robust subjects: miR-451a serum concentration was significantly increased (frail: 6.59 x 10.sup.4; 1.12 x 10.sup.4-2.5 x 10.sup.5 c/ng; robust: 2.31 x 10.sup.4; 1.94 x 10.sup.3-2.01 x 10.sup.5 c/ng) (p < 0.05); and 2) miR-93-5p and miR-495-3p serum concentration was reduced, whereas that of miR-155-5p was significantly increased (p < 0.05 in both cases). Serum concentration of miR-93-5p and miR-495-3p was decreased, and that of miR-155-5p was increased at the end of the program in robust subjects alone, statistical significance being reached for miR-93-5p alone (p = 0.02). Conclusion These results suggest that serum miR-451a should be investigated as a potential biomarker for frailty and show that the VIVIFRAIL multicomponent program modulates circulatory miRNAs expression, at least in older adults. Keywords: microRNA, Sarcopenia, Frailty, Rehabilitation, Physical Activity, Biomarkers Abstract Background Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene expression; miRNAs are present in serum and are considered potential biomarkers for several diseases. Serum concentration of miR-451a, miR-93-5p, miR-155-5p, miR-421-3p, miR-425-5p, miR-495-3p and miR-744-5p was recently shown to be altered in sarcopenic patients. Methods We verified if a particular miRNAs pattern could be detected in frailty as well by analyzing these molecules in 50 frail and 136 robust subjects. Additionally, a subgroup of these subjects (15 frail and 30 robust) underwent a 12-week program based on a multicomponent exercise protocol (VIVIFRAIL) consisting of resistance training, gait retraining, and balance training. After the program, serum miRNAs concentration was measured again, to verify whether the physical activity had an effect on their concentration. Moreover, clinical characteristics and indicators of physical performance of all subjects were compared before and after intervention to verify the effect of the VIVIFRAIL program. Results At the end of the multicomponent exercise program, Short Physical Performance Battery (SPPB) score as well right and left handgrip (p < 0.05) were significantly increased in frail subjects; right and left handgrip significantly were increased also in robust subjects (p < 0.05). Interestingly, the variation of SPPB was significantly higher in frail compared to robust subjects (p < 0.0001). Moreover, at the end of the program, in frail compared to robust subjects: miR-451a serum concentration was significantly increased (frail: 6.59 × 104; 1.12 × 104–2.5 × 105 c/ng; robust: 2.31 × 104; 1.94 × 103–2.01 × 105 c/ng) (p < 0.05); and 2) miR-93-5p and miR-495-3p serum concentration was reduced, whereas that of miR-155-5p was significantly increased (p < 0.05 in both cases). Serum concentration of miR-93-5p and miR-495-3p was decreased, and that of miR-155-5p was increased at the end of the program in robust subjects alone, statistical significance being reached for miR-93-5p alone (p = 0.02). Conclusion These results suggest that serum miR-451a should be investigated as a potential biomarker for frailty and show that the VIVIFRAIL multicomponent program modulates circulatory miRNAs expression, at least in older adults. Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric syndrome characterized by loss of muscle strength and mass. microRNAs (miRNAs) are short molecules of RNA endowed with the ability to modulate gene expression; miRNAs are present in serum and are considered potential biomarkers for several diseases. Serum concentration of miR-451a, miR-93-5p, miR-155-5p, miR-421-3p, miR-425-5p, miR-495-3p and miR-744-5p was recently shown to be altered in sarcopenic patients. We verified if a particular miRNAs pattern could be detected in frailty as well by analyzing these molecules in 50 frail and 136 robust subjects. Additionally, a subgroup of these subjects (15 frail and 30 robust) underwent a 12-week program based on a multicomponent exercise protocol (VIVIFRAIL) consisting of resistance training, gait retraining, and balance training. After the program, serum miRNAs concentration was measured again, to verify whether the physical activity had an effect on their concentration. Moreover, clinical characteristics and indicators of physical performance of all subjects were compared before and after intervention to verify the effect of the VIVIFRAIL program. At the end of the multicomponent exercise program, Short Physical Performance Battery (SPPB) score as well right and left handgrip (p < 0.05) were significantly increased in frail subjects; right and left handgrip significantly were increased also in robust subjects (p < 0.05). Interestingly, the variation of SPPB was significantly higher in frail compared to robust subjects (p < 0.0001). Moreover, at the end of the program, in frail compared to robust subjects: miR-451a serum concentration was significantly increased (frail: 6.59 x 10.sup.4; 1.12 x 10.sup.4-2.5 x 10.sup.5 c/ng; robust: 2.31 x 10.sup.4; 1.94 x 10.sup.3-2.01 x 10.sup.5 c/ng) (p < 0.05); and 2) miR-93-5p and miR-495-3p serum concentration was reduced, whereas that of miR-155-5p was significantly increased (p < 0.05 in both cases). Serum concentration of miR-93-5p and miR-495-3p was decreased, and that of miR-155-5p was increased at the end of the program in robust subjects alone, statistical significance being reached for miR-93-5p alone (p = 0.02). These results suggest that serum miR-451a should be investigated as a potential biomarker for frailty and show that the VIVIFRAIL multicomponent program modulates circulatory miRNAs expression, at least in older adults. |
| ArticleNumber | 67 |
| Audience | Academic |
| Author | Agostini, Simone Mihali, Gabriela Alexandra Mancuso, Roberta Clerici, Mario Arosio, Beatrice Citterio, Lorenzo Agostino |
| Author_xml | – sequence: 1 givenname: Simone surname: Agostini fullname: Agostini, Simone – sequence: 2 givenname: Roberta orcidid: 0000-0002-4449-3623 surname: Mancuso fullname: Mancuso, Roberta – sequence: 3 givenname: Lorenzo Agostino surname: Citterio fullname: Citterio, Lorenzo Agostino – sequence: 4 givenname: Gabriela Alexandra surname: Mihali fullname: Mihali, Gabriela Alexandra – sequence: 5 givenname: Beatrice surname: Arosio fullname: Arosio, Beatrice – sequence: 6 givenname: Mario surname: Clerici fullname: Clerici, Mario |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36726153$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1r3DAQhk1JaT7aP9BDEfSSHpzqy5J1KSwhaReWFkKbqxjL8laLLW0lO6T99ZV3k5CEUnSQ0LzzaGb0HhcHPnhbFG8JPiOkFh8ToUrIElNWYqYIKdmL4ohwqcqqluLg0fmwOE5pgzHlFVevikMmJBWkYkfFn4sb6CcYXfAodCjZOA1ocFdfFwnZ2220Kc0h51EXwfUIfItiaKY0ojQ1G2vGhCbf2rgOzq_RMPWjM2HY5kr9mAk2Gpcs2sYwBhN6dHq9vF5eXi2Wqw-vi5cd9Mm-udtPih-XF9_Pv5Srb5-X54tVaSrBxhLqGuOqI1xYrgSGGqiy2BJMKGuB8Y4CaxS0MquYZS3nhtCqajgnTcdYx06K5Z7bBtjobXQDxN86gNO7ixDXGmKuure6kUBqqIBSJnjXChBAAbChTLV1fimzPu1Z26kZbGtykxH6J9CnEe9-6nW40apWpFZVBpzeAWL4Ndk06sElY_sevA1T0lRKojgljGXp-2fSTZiiz6OaVVLWQuYBPajWkBtwvgv5XTND9UKyquKMyrnus3-o8mrtkP_L287l-ycJ7x43-tDhvXOyoN4LTAwpRdtp48adj8bZKJpgPZtU702qs0n1zqR6TqXPUu_p_0n6C61L6Jo |
| CitedBy_id | crossref_primary_10_3390_ijms252312872 crossref_primary_10_1016_j_exger_2024_112600 crossref_primary_10_1016_j_mam_2024_101271 crossref_primary_10_1016_j_exger_2024_112670 crossref_primary_10_2217_epi_2023_0279 crossref_primary_10_1016_j_jnha_2024_100401 crossref_primary_10_3390_cimb46040212 |
| Cites_doi | 10.3389/fphys.2021.678610 10.1002/jcsm.12512 10.3389/fphys.2017.00383 10.4161/adip.20344 10.1111/liv.12636 10.3389/fonc.2022.765163 10.1016/j.freeradbiomed.2018.08.035 10.1007/s40520-016-0716-1 10.3389/fimmu.2017.01960 10.1016/j.exger.2016.09.007 10.1371/journal.pone.0153200 10.1007/s11033-020-05862-0 10.1016/j.nut.2011.12.002 10.1016/0092-8674(93)90529-Y 10.1074/jbc.RA118.003862 10.1038/s41416-021-01677-3 10.18632/aging.100598 10.2174/1389203718666170607113459 10.3390/jfmk3020036 10.1002/jcsm.12259 10.1186/s12967-021-02830-5 10.1056/NEJMcp0910237 10.1111/jcmm.15197 10.1016/j.arr.2021.101530 10.1186/s12877-021-02030-2 10.2147/CIA.S149232 10.1093/nar/gkt1181 10.1002/jcp.28986 10.1016/S0140-6736(19)31786-6 10.3390/genes13030425 10.1016/j.ceb.2009.01.029 10.1300/J018v05n01_09 10.1016/j.jaci.2017.08.034 10.3389/fimmu.2021.685344 10.1093/ageing/afy169 10.3233/CBM-201547 10.1016/j.cger.2015.04.005 10.1093/geronj/49.2.M85 10.1016/j.maturitas.2011.11.012 10.1038/s41598-019-43978-x 10.1093/gerona/63.8.829 10.1186/s13063-019-3426-0 10.1093/geront/9.3_Part_1.179 10.1016/S0140-6736(12)62167-9 10.1186/s12967-021-02989-x 10.1093/gerona/56.3.M146 10.1007/s11033-021-07010-8 10.1016/j.exger.2018.09.017 10.1161/CIRCRESAHA.111.247437 10.1038/s41598-017-16113-x 10.1016/j.jamda.2011.04.014 10.4049/jimmunol.1201437 10.1177/17246008211070018 10.1002/gps.930010209 10.21037/atm-22-97 |
| ContentType | Journal Article |
| Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
| Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12967-023-03911-3 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Proquest Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_b7a18a5a22364fd6a6a2aa0c239d84f2 PMC9891895 A735543272 36726153 10_1186_s12967_023_03911_3 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Italy United States--US |
| GeographicLocations_xml | – name: Italy – name: United States--US |
| GrantInformation_xml | – fundername: ; – fundername: ; grantid: 2017-0622 – fundername: ; grantid: RC2021-2023 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7T5 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c563t-a88005f146e4960a8a29e0e10123da34f2a3b9ad70053e3d44c1255b441bf33f3 |
| IEDL.DBID | M48 |
| ISSN | 1479-5876 |
| IngestDate | Wed Aug 27 01:25:55 EDT 2025 Thu Aug 21 18:38:14 EDT 2025 Tue Aug 05 10:39:11 EDT 2025 Fri Jul 25 05:27:57 EDT 2025 Tue Jun 17 21:28:13 EDT 2025 Tue Jun 10 20:33:33 EDT 2025 Thu Jan 02 22:53:54 EST 2025 Tue Jul 01 02:59:38 EDT 2025 Thu Apr 24 23:00:59 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Biomarkers Sarcopenia Frailty microRNA Rehabilitation Physical Activity |
| Language | English |
| License | 2023. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c563t-a88005f146e4960a8a29e0e10123da34f2a3b9ad70053e3d44c1255b441bf33f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-4449-3623 |
| OpenAccessLink | https://www.proquest.com/docview/2777786756?pq-origsite=%requestingapplication% |
| PMID | 36726153 |
| PQID | 2777786756 |
| PQPubID | 43076 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b7a18a5a22364fd6a6a2aa0c239d84f2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9891895 proquest_miscellaneous_2771942133 proquest_journals_2777786756 gale_infotracmisc_A735543272 gale_infotracacademiconefile_A735543272 pubmed_primary_36726153 crossref_citationtrail_10_1186_s12967_023_03911_3 crossref_primary_10_1186_s12967_023_03911_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-02-02 |
| PublicationDateYYYYMMDD | 2023-02-02 |
| PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2023 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | J Chen (3911_CR40) 2022; 37 CM Rosenberger (3911_CR49) 2012; 189 F Landi (3911_CR13) 2015; 31 F Landi (3911_CR14) 2018; 19 B Roy (3911_CR19) 2022; 13 V Malafrina (3911_CR9) 2012; 71 RC Lee (3911_CR20) 1993; 75 X Zou (3911_CR48) 2021; 30 JE Morley (3911_CR6) 2011; 12 A Clegg (3911_CR1) 2013; 381 S Rana (3911_CR51) 2022; 126 T Fulop (3911_CR12) 2018; 8 S Kelch (3911_CR55) 2017; 7 Z Zhang (3911_CR46) 2020; 2020 F La Rosa (3911_CR60) 2021; 19 WRP Van de Worp (3911_CR39) 2020; 11 RF D’Souza (3911_CR42) 2017; 8 L Zavesky (3911_CR41) 2022; 49 BC Clark (3911_CR4) 2008; 63 M Cesari (3911_CR24) 2017; 29 KI Shulman (3911_CR31) 1986; 1 H Oshiumi (3911_CR47) 2021; 12 N He (3911_CR54) 2021; 12 YY Shen (3911_CR38) 2018; 22 F Curcio (3911_CR35) 2016; 85 EO Hoogendijk (3911_CR3) 2019; 394 EM Mercken (3911_CR44) 2013; 5 MP Lawton (3911_CR29) 1969; 9 BC Clark (3911_CR5) 2012; 28 V Vaira (3911_CR50) 2015; 5 JM Guralnik (3911_CR28) 1994; 49 A Picca (3911_CR15) 2022; 73 JA Yesavage (3911_CR32) 2008; 5 L Yang (3911_CR52) 2022; 12 L Pedersen (3911_CR10) 2012; 1 AJ Cruz-Jentoft (3911_CR8) 2019; 48 JL Barber (3911_CR58) 2019; 9 A Kozomara (3911_CR37) 2014; 42 E Marzetti (3911_CR25) 2018; 113 RM Sapp (3911_CR57) 1985; 2017 JS Shah (3911_CR33) 2016; 11 J Yin (3911_CR18) 2020; 24 I Liguori (3911_CR36) 2018; 13 PK Davidsen (3911_CR43) 1985; 2011 LP Fried (3911_CR2) 2001; 56 LM Margolis (3911_CR59) 2017; 72 AH Williams (3911_CR16) 2009; 21 CM Nascimento (3911_CR56) 2019; 132 M Xu (3911_CR17) 2020; 235 S Agostini (3911_CR34) 2020; 47 BA Baker (3911_CR7) 2018; 3 M Okamoto (3911_CR45) 2018; 293 A Casas-Herrero (3911_CR27) 2019; 20 S Agostini (3911_CR23) 2021; 19 M Petrella (3911_CR26) 2021; 21 TX Lu (3911_CR22) 2018; 141 M Abdellatif (3911_CR21) 2012; 110 AF Pagano (3911_CR11) 2018; 9 RC Petersen (3911_CR30) 2011; 364 M Yang (3911_CR53) 2022; 10 |
| References_xml | – volume: 12 year: 2021 ident: 3911_CR54 publication-title: Front Physiol doi: 10.3389/fphys.2021.678610 – volume: 72 start-page: 1319 year: 2017 ident: 3911_CR59 publication-title: J Gerontol A Biol Sci Med Sci – volume: 11 start-page: 452 year: 2020 ident: 3911_CR39 publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12512 – volume: 8 start-page: 383 year: 2017 ident: 3911_CR42 publication-title: Front Physiol doi: 10.3389/fphys.2017.00383 – volume: 1 start-page: 164 year: 2012 ident: 3911_CR10 publication-title: Adipocyte doi: 10.4161/adip.20344 – volume: 5 start-page: 1077 year: 2015 ident: 3911_CR50 publication-title: Liver Int doi: 10.1111/liv.12636 – volume: 12 year: 2022 ident: 3911_CR52 publication-title: Front Oncol doi: 10.3389/fonc.2022.765163 – volume: 132 start-page: 42 year: 2019 ident: 3911_CR56 publication-title: Free Radical Biol Med doi: 10.1016/j.freeradbiomed.2018.08.035 – volume: 29 start-page: 81 year: 2017 ident: 3911_CR24 publication-title: Aging Clin Exp Res doi: 10.1007/s40520-016-0716-1 – volume: 8 start-page: 1960 year: 2018 ident: 3911_CR12 publication-title: Front Immunol doi: 10.3389/fimmu.2017.01960 – volume: 85 start-page: 1 year: 2016 ident: 3911_CR35 publication-title: Exp Gerontol doi: 10.1016/j.exger.2016.09.007 – volume: 2020 start-page: 5236326 year: 2020 ident: 3911_CR46 publication-title: Biomed Res Int – volume: 11 year: 2016 ident: 3911_CR33 publication-title: PLoS ONE doi: 10.1371/journal.pone.0153200 – volume: 47 start-page: 9201 year: 2020 ident: 3911_CR34 publication-title: Mol Biol Rep doi: 10.1007/s11033-020-05862-0 – volume: 28 start-page: 495 year: 2012 ident: 3911_CR5 publication-title: Nutrition doi: 10.1016/j.nut.2011.12.002 – volume: 75 start-page: 843 year: 1993 ident: 3911_CR20 publication-title: Cell doi: 10.1016/0092-8674(93)90529-Y – volume: 293 start-page: 18585 year: 2018 ident: 3911_CR45 publication-title: J Biol Chem doi: 10.1074/jbc.RA118.003862 – volume: 126 start-page: 502 year: 2022 ident: 3911_CR51 publication-title: Br J Cancer doi: 10.1038/s41416-021-01677-3 – volume: 5 start-page: 692 year: 2013 ident: 3911_CR44 publication-title: Aging (Albany NY) doi: 10.18632/aging.100598 – volume: 2011 start-page: 165 issue: 18 year: 1985 ident: 3911_CR43 publication-title: J Appl Physiol – volume: 19 start-page: 633 year: 2018 ident: 3911_CR14 publication-title: Curr Protein Pept Sci doi: 10.2174/1389203718666170607113459 – volume: 3 start-page: 36 year: 2018 ident: 3911_CR7 publication-title: J Funct Morphol Kinesiol doi: 10.3390/jfmk3020036 – volume: 9 start-page: 335 year: 2018 ident: 3911_CR11 publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12259 – volume: 19 start-page: 172 year: 2021 ident: 3911_CR60 publication-title: J Transl Med doi: 10.1186/s12967-021-02830-5 – volume: 364 start-page: 2227 year: 2011 ident: 3911_CR30 publication-title: N Engl J Med doi: 10.1056/NEJMcp0910237 – volume: 24 start-page: 4900 year: 2020 ident: 3911_CR18 publication-title: J Cell Mol Med doi: 10.1111/jcmm.15197 – volume: 73 year: 2022 ident: 3911_CR15 publication-title: Agein Res Rev doi: 10.1016/j.arr.2021.101530 – volume: 21 start-page: 83 year: 2021 ident: 3911_CR26 publication-title: BMC Geriatr doi: 10.1186/s12877-021-02030-2 – volume: 13 start-page: 913 year: 2018 ident: 3911_CR36 publication-title: Clin Interv Aging doi: 10.2147/CIA.S149232 – volume: 42 start-page: D68 year: 2014 ident: 3911_CR37 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkt1181 – volume: 235 start-page: 87 year: 2020 ident: 3911_CR17 publication-title: J Cell Phyisol doi: 10.1002/jcp.28986 – volume: 394 start-page: 1365 year: 2019 ident: 3911_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(19)31786-6 – volume: 13 start-page: 425 year: 2022 ident: 3911_CR19 publication-title: Genes (Basel) doi: 10.3390/genes13030425 – volume: 21 start-page: 461 year: 2009 ident: 3911_CR16 publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2009.01.029 – volume: 5 start-page: 165 year: 2008 ident: 3911_CR32 publication-title: Clin Gerontologist doi: 10.1300/J018v05n01_09 – volume: 141 start-page: 1202 year: 2018 ident: 3911_CR22 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.08.034 – volume: 12 year: 2021 ident: 3911_CR47 publication-title: Front Immunol doi: 10.3389/fimmu.2021.685344 – volume: 2017 start-page: 702 issue: 122 year: 1985 ident: 3911_CR57 publication-title: J Appl Physiol – volume: 48 start-page: 16 year: 2019 ident: 3911_CR8 publication-title: Age Ageing doi: 10.1093/ageing/afy169 – volume: 30 start-page: 41 year: 2021 ident: 3911_CR48 publication-title: Cancer Biomark doi: 10.3233/CBM-201547 – volume: 31 start-page: 367 year: 2015 ident: 3911_CR13 publication-title: Clin Geriatr Med doi: 10.1016/j.cger.2015.04.005 – volume: 49 start-page: M85 year: 1994 ident: 3911_CR28 publication-title: J Gerontol doi: 10.1093/geronj/49.2.M85 – volume: 71 start-page: 109 year: 2012 ident: 3911_CR9 publication-title: Maturitas doi: 10.1016/j.maturitas.2011.11.012 – volume: 22 start-page: 5554 year: 2018 ident: 3911_CR38 publication-title: Eur Rev Med Pharmacol Sci – volume: 9 start-page: 7527 year: 2019 ident: 3911_CR58 publication-title: Sci Rep doi: 10.1038/s41598-019-43978-x – volume: 63 start-page: 829 year: 2008 ident: 3911_CR4 publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/63.8.829 – volume: 20 start-page: 362 year: 2019 ident: 3911_CR27 publication-title: Trials doi: 10.1186/s13063-019-3426-0 – volume: 9 start-page: 179 year: 1969 ident: 3911_CR29 publication-title: Gerontologist doi: 10.1093/geront/9.3_Part_1.179 – volume: 381 start-page: 752 year: 2013 ident: 3911_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(12)62167-9 – volume: 19 start-page: 315 year: 2021 ident: 3911_CR23 publication-title: J Transl Med doi: 10.1186/s12967-021-02989-x – volume: 56 start-page: M146 year: 2001 ident: 3911_CR2 publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/56.3.M146 – volume: 49 start-page: 1955 year: 2022 ident: 3911_CR41 publication-title: Mol Biol Rep doi: 10.1007/s11033-021-07010-8 – volume: 113 start-page: 48 year: 2018 ident: 3911_CR25 publication-title: Exp Gerontol doi: 10.1016/j.exger.2018.09.017 – volume: 110 start-page: 638 year: 2012 ident: 3911_CR21 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.111.247437 – volume: 7 start-page: 15861 year: 2017 ident: 3911_CR55 publication-title: Sci Rep doi: 10.1038/s41598-017-16113-x – volume: 12 start-page: 403 year: 2011 ident: 3911_CR6 publication-title: J Am Med Dir Assoc doi: 10.1016/j.jamda.2011.04.014 – volume: 189 start-page: 5965 year: 2012 ident: 3911_CR49 publication-title: J Immunol doi: 10.4049/jimmunol.1201437 – volume: 37 start-page: 74 year: 2022 ident: 3911_CR40 publication-title: Int J Biol Markers doi: 10.1177/17246008211070018 – volume: 1 start-page: 135 year: 1986 ident: 3911_CR31 publication-title: Int J Geriatr Psychiatry doi: 10.1002/gps.930010209 – volume: 10 start-page: 203 year: 2022 ident: 3911_CR53 publication-title: Ann Transl Med doi: 10.21037/atm-22-97 |
| SSID | ssj0024549 |
| Score | 2.4259965 |
| Snippet | Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a geriatric... Background Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a... BackgroundFrailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of sarcopenia, a... Abstract Background Frailty, defined as physical performance impairment, is a common condition in older adults and can anticipate the development of... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 67 |
| SubjectTerms | Aged Analysis Balance Biological markers Biomarkers Care and treatment Exercise Frail Elderly Frailty Frailty - genetics Gait Gene expression Hand Strength Health aspects Humans MicroRNA MicroRNAs MicroRNAs - genetics miRNA Muscle strength Older people Physical Activity Physical fitness Physical training Prevention Rehabilitation Risk factors Sarcopenia Software |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFB6kD-KLWK_RKiMIKhKauWQuj6t06Yr2odjSt-FMMtGFNpHNBoq_3jO5LBsEfRHylDkhc-bckzPfEPIGMOXnlfcp5hY2lbwM6AdNkdrMZlnJdGmHLt8zdXohP1_lV3tHfcWesAEeeFi4Y6-BGciBR6TzqlSggANkBRe2NLLqvS_GvKmYmlD2sOyZtsgYddxiVEOHgPEpjYjoLBWzMNSj9f_pk_eC0rxhci8CLR-Q-2PqSBfDlA_JnVA_JHe_jj_HH5FfJzvkbtpUFHWru6E36_OzRUvD7djwWtN1TasNrK8p1CXdNL5rt7TtfPwe09K4pWzzvcF4RvtWw9hx3tQ4HzqdzUQjskOD6kPfXa4uV8vzxerL-8fkYnny7dNpOh6tkBa5EtsU0GyzvEI3GSTWMGCA25CFCPYlShC4riC8hVJHIw2ilLLATCj3mDz5SohKPCEHNb7-GaFglVfAqsAglxIqI0LBtPGAlaOS4BPCppV2xYg7Ho-_uHZ9_WGUG6TjUDqul44TCfmwe-bngLrxV-qPUYA7yoiY3d9APXKjHrl_6VFC3kbxu2jXOL0Cxu0JyGREyHILHTMzwTVSHs0o0R6L-fCkQG70B63jWkegPp2rhLzeDccnY49bHZqup2FWciaQoaeDvu1YEkrzmJonRM80ccbzfKRe_-jRwq2xzNj8-f9YpBfkHu-NiON1RA62my68xKRs61_19vcbmaMzEw priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbB2MvY9_L2g0NBtsYprYkS9bTyEZDM7Y-lLXkTZxsuQ20dhcnUPbX785R0ppBIU_Rmehy3_Lpd4x9AEz5Re19grmFTZSoAvrBokxsatO0ykxl112-R_rwRP2Y5bN44NbFtsqNT-wdddWWdEa-L4whqDOT669XfxKaGkVvV-MIjfvsAUGXUUuXmd0UXAqLn81FmULvdxjb0C1glEoIFz1L5CAY9Zj9_3vmW6Fp2DZ5Kw5NnrDHMYHk47XEn7J7oXnGHv6Kr8ifs78HW_xu3tYcNWx1yS_nx0fjjofr2Pba8HnD6wXMLzg0FV-0ftUtebfydCrTcbpYtjhrMarxvuGQ-s7bBvfDNxOaOOE7tKhE_NPp9HQ6OR5Pf35-wU4mB7-_HyZxwEJS5louE0DjTfManWVQWMlAAcKGNBDkl6xAqlqA9BYqQ6YaZKVUiflQ7jGF8rWUtXzJdhr8-deMg9VeQ1aHDHKloC5kKDNTeMD6USvwI5Zt_mlXRvRxGoJx4foqpNBuLR2H0nG9dJwcsS_bZ67W2Bt3Un8jAW4pCTe7_6JdnLlohs4byArIQRBufl1p0CAA0lJIWxXI74h9JPE7sm7cXgnxkgIySThZbmwoP5PCIOXegBKtshwubxTIRa_QuRsdHrH322V6kjrdmtCueprMKpFJZOjVWt-2LEltBCXoI2YGmjjgebjSzM97zHBb2Kyw-Zu7t7XLHonePAR-9tjOcrEKbzHpWvp3vWX9A0X2Kmo priority: 102 providerName: ProQuest |
| Title | Evaluation of serum miRNAs expression in frail and robust subjects undergoing multicomponent exercise protocol (VIVIFRAIL) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36726153 https://www.proquest.com/docview/2777786756 https://www.proquest.com/docview/2771942133 https://pubmed.ncbi.nlm.nih.gov/PMC9891895 https://doaj.org/article/b7a18a5a22364fd6a6a2aa0c239d84f2 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9NAEF_uA8QX8dueZ1lBUJFosrvJZh9EWmm5ilek2KP4sszm4yz0kjNp4fSvd3ab1AseglDy0J2kuzvz25lNZ39DyAvAkJ_lxngYWyhPsDTDdTBOPOUr308Dmaptlu80OpmLT4twsUfackfNBNY3bu1sPal5tXp79ePnBwT8ewf4OHpXo89CuKP38SzfeeDxfXKInklaoJ6K-A_3XujC4UBgt0JcBtpDNDc-o-OoHJ__36v2NbfVTam85qPGd8mdJrikg6013CN7WXGf3Dpt_j5_QH6NdtzetMwpWt_mgl4sZ9NBTbOrJiW2oMuC5hUsVxSKlFal2dRrWm-MfWNTU3vorDov0eNRl4xoc9LLAvtD2-pN1HI_lGhg9NXZ5Gwyng0mn18_JPPx6OvHE68pvuAlYcTXHiCw_TDHhTQTuMuBGJjK_MzSgfEUuMgZcKMglRbGGU-FSDBWCg2GVybnPOePyEGBP_-EUFCRiSDIswBCISCPeZYEMjaAe8tIgOmRoJ1pnTTM5LZAxkq7HUoc6a12NGpHO-1o3iNvdvdcbnk5_ik9tArcSVpObfdFWZ3rBqLaSAhiCIFZTv08jSACBuAnjKs0xvH2yEurfm1tEbuXQHOAAQdpObT0QNrYjTOJkscdSURs0m1uDUi3Bq-ZlJbKT4ZRjzzfNds7bRZckZUbJxMowQKOA3q8tbfdkHgkmQ3ee0R2LLEz5m5Lsfzu-MRVrIJYhUf_NaVPyW3m0MLwc0wO1tUme4bx2dr0yb5cyD45HI6mX2Z995aj74CI19nw228q3jeo |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVAIuiDeBAosEAlRZtXf92gNCKSRKaBqhqK16W2btdYnU2iVOxONH8RuZcey0FlJvlXLKjpMdz9ue_Yax14Apv8iMcTC3UI4vUot-ME4c5SrXTb0oVasu30k4PPS_HAfHG-xvcxaG2iobn1g56rRI6Bn5jogigjqLgvDj-Q-HpkbR29VmhMZKLfbs759YspUfRp9Rvm-EGPQPPg2deqqAkwShXDiAGusGGXoI62P6DjEIZV1LOFcyBelnAqRRkEakn1amvp9gEhAYzBtMJmUm8XdvsE1fYinTYZu7_cnX6QW6H5ZbzdGcONwpMZqiI8K46BASu-fIVvirpgT8HwsuBcN2o-alyDe4y-7UKSvvrXTsHtuw-X12c79-Kf-A_emvEcN5kXHU6eUZP5tNJ72S2191o23OZznP5jA75ZCnfF6YZbng5dLQc6CS01G2-UmBcZRXLY7U6V7kuB_ezITihChRoNryd0ejo9Fg2huN3z9kh9dy8x-xTo5__4RxUKEJwcusB4HvQxZLm3hRbAAr1tAH02Vec6d1UuOd09iNU13VPXGoV9LRKB1dSUfLLtteX3O-Qvu4knqXBLimJKTu6otifqJrw9cmAi-GAAQh9WdpCCEIADcRUqUx8ttlb0n8mvwJbi-B-lgEMknIXLoXUUYoRYSUWy1K9ANJe7lRIF37oVJfWE2XvVov05XUW5fbYlnReMoXnkSGHq_0bc2SDCNBJUGXRS1NbPHcXsln3yuUchUrL1bB06u39ZLdGh7sj_V4NNl7xm6LylQEfrZYZzFf2ueY8i3Mi9rOOPt23ab9Dy7BZwc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+serum+miRNAs+expression+in+frail+and+robust+subjects+undergoing+multicomponent+exercise+protocol+%28VIVIFRAIL%29&rft.jtitle=Journal+of+translational+medicine&rft.au=Agostini%2C+Simone&rft.au=Mancuso%2C+Roberta&rft.au=Citterio%2C+Lorenzo+Agostino&rft.au=Mihali%2C+Gabriela+Alexandra&rft.date=2023-02-02&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-023-03911-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12967_023_03911_3 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |